INTERVIEW: Genedrive Plc Funding to execute commercial strategy

Genedrive Plc (LON:GDR) is the topic of conversation when Hardman & Co, life sciences Analyst Dr Dorothea Hill talks to DirectorTalk. Dorothea explains the significance of the recent fundraise, how the proceeds with be used, what stage the technology is currently at, why she considers the commercial potential of Genedrive technology so great and thoughts on the current company valuation.

Genedrive plc is a commercial-stage company focused on point-of-care molecular diagnostics. Its Genedrive(R) molecular diagnostic testing platform is at the forefront of this technology, offering a rapid, low-cost, simple-to-use device with high sensitivity and specificity in the diagnosis of infectious diseases. Rapid analysis of patient samples greatly aids clinical and public health decision-making, with field testing particularly important in emerging markets. The 2018 fiscal year saw solid operational progress to generate first commercial sales. CE marking of the assay for hepatitis C virus (HCV) detection was awarded, and three commercial partnerships were agreed.

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    Twitter
    LinkedIn
    Hardman & Co

    More articles like this

    Hardman & Co

    Genedrive Plc Western market progress but developing markets difficult

    Genedrive plc (LON:GDR) is a commercial-stage biotech focused on point-of-care molecular diagnostics. Its Genedrive® molecular diagnostic platform offers low-cost, simple-to-use devices for highly sensitive and specific testing. The rapid analysis of samples aids real-time decision-making, whether

    Hardman & Co

    Genedrive Regulatory hurdle leaped: hearing loss assay

    Genedrive (LON:GDR) is a commercial-stage company focused on point-of-care molecular diagnostics. Its Genedrive® molecular diagnostic platform is at the forefront of this technology, offering a rapid, low-cost, simple-to-use device with high sensitivity and specificity. Rapid analysis

    Hardman & Co

    Genedrive – Acceleration of news flow expected

    Genedrive plc (LON:GDR) is the topic of conversation when Dr Dorothea Hill joins DirectorsTalk. After releasing a note anticipating accelerated news flow from Genedrive Dorothea gives us an update as to what has been happening within the

    Hardman & Co

    Genedrive plc First commercial sales in new focus area: bio-threats

    Genedrive plc (LON:GDR) is a commercial-stage company focused on point-of-care (PoC) molecular diagnostics. Its Genedrive® molecular diagnostic platform is at the forefront of this technology, offering a rapid, low-cost, simple-to-use device with high sensitivity and specificity

    Hardman & Co

    Genedrive plc Accelerating into fiscal 2019 with first sales

    Genedrive plc (LON:GDR) is a commercial-stage company focused on point-of-care molecular diagnostics. Its Genedrive® molecular diagnostic testing platform is at the forefront of this technology, offering a rapid, low-cost, simple-to-use device with high sensitivity and specificity

    Hardman & Co

    Genedrive plc Preventing hearing loss in newborns

    Genedrive plc (LON:GDR) is a commercial-stage company focused on point-of-care molecular diagnostics. Its Genedrive® molecular diagnostic testing platform is at the forefront of this technology, offering a rapid, low-cost, simple-to-use device with high sensitivity and specificity

    Hardman & Co

    genedrive plc Remodelled for growth

    genedrive plc (LON:GDR) is a commercial-stage company focused on point-of-care/need molecular diagnostics and biomarkers. Its Genedrive® in vitro diagnostic testing platform is at the forefront of this technology, offering a rapid, low-cost, simple-to-use device with high